Synergistic antitumor effect of folate-targeted Pluronic™ F-127/poly(lactic acid) polymersomes for codelivery of doxorubicin and paclitaxel

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Zhao N, Woodle MC, Mixson AJ. Advances in delivery systems for doxorubicin. J. Nanomed. Nanotechnol. 9(5), 519 (2018). •• Considers the development of drug-delivery systems for doxorubicin (DOX), which address the limitations of free DOX formulations.
  MedlineGoogle Scholar
• 2. Zanden SY, Qiao XH, Neefjes J. New insights into the activities and toxicities of the old anticancer drug doxorubicin. FEBS J. 288(21), 6095–6111 (2021).
  MedlineGoogle Scholar
• 3. Zhu LY, Chen LQ. Progress in research on paclitaxel and tumor immunotherapy. Cell. Mol. Biol. Lett. 24, 40 (2019). • Summarizes recent advances in the sources, the anticancer mechanism and the biosynthetic pathway of paclitaxel (PTX).
  Medline CASGoogle Scholar
• 4. Schmid P, Adams S, Rugo HS et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 379(22), 2108–2121 (2018).
  Medline CASGoogle Scholar
• 5. Sandamali JAN, Hewawasam RP, Jayatilaka KAPW, Mudduwa LKB. Cinnamomum zeylanicum Blume (Ceylon cinnamon) bark extract attenuates doxorubicin induced cardiotoxicity in Wistar rats. Saudi Pharm. J. 29(8), 820–832 (2021).
  Medline CASGoogle Scholar
• 6. Carvalho C, Santos RX, Cardoso S et al. Doxorubicin: the good, the bad and the ugly effect. Curr. Med. Chem. 16(25), 3267–3285 (2009).
  Medline CASGoogle Scholar
• 7. Sharifi-Rad J, Quispe C, Patra JK et al. Paclitaxel: application in modern oncology and nanomedicine-based cancer therapy. Oxid. Med. Cell. Longev. 2021, 3687700 (2021). •• Reviews the current state of continuous pharmaceutical development and use of nanotechnology in enhancing the pharmacokinetic and pharmacodynamic features of PTX as a chemotherapeutic agent.
  MedlineGoogle Scholar
• 8. Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int. J. Pharm. 235(1–2), 179–192 (2002).
  Medline CASGoogle Scholar
• 9. Chen YZ, Zhang W, Huang YK et al. Pluronic-based functional polymeric mixed micelles for co-delivery of doxorubicin and paclitaxel to multidrug resistant tumor. Int. J. Pharm. 488(1–2), 44–58 (2015). •• The dual drug-loaded mixed micelles in this study would offer great advantages over conventional micelles, including easy fabrication, high loading capacity and codelivery of hydrophilic DOX and hydrophobic PTX to achieve a synergistic effect.
  Medline CASGoogle Scholar
• 10. Radhakrishnan ML, Tidor B. Optimal drug cocktail design: methods for targeting molecular ensembles and insights from theoretical model systems. J. Chem. Inf. Model. 48(5), 1055–1073 (2008).
  Medline CASGoogle Scholar
• 11. Li WL, Zhang WJ, Yang XY, Xie ZG, Jing XB. Biodegradable polymersomes from four-arm PEG-b-PDLLA for encapsulating hemoglobin. J. Appl. Polym. Sci. 131(12), 40433 (2014).
  Google Scholar
• 12. Nehate C, Raynold AAM, Haridas V, Koul V. Comparative assessment of active targeted redox sensitive polymersomes based on pPEGMA-SS-PLA diblock copolymer with marketed nanoformulation. Biomacromolecules 19(7), 2549–2566 (2018). • The polymersomes formulation was optimized by providing monodisperse nanostructures of ∼110 nm and enhanced DOX loading of ∼20%.
  Medline CASGoogle Scholar
• 13. Ayen WY, Garkhal K, Kumar N. Doxorubicin-loaded (PEG) 3-PLA nanopolymersomes: effect of solvents and process parameters on formulation development and in vitro study. Mol. Pharm. 8(2), 466–478 (2011).
  Medline CASGoogle Scholar
• 14. Deng ZY, Liu SY. Emerging trends in solution self-assembly of block copolymers. Polymer 207, 122914 (2020).
  CASGoogle Scholar
• 15. Tai WY, Mo R, Di J et al. Bio-inspired synthetic nanovesicles for glucose-responsive release of insulin. Biomacromolecules 15(10), 3495–3502 (2014).
  Medline CASGoogle Scholar
• 16. Kulkarni PS, Haldar MK, Nahire RR et al. MMP-9 Responsive PEG cleavable nanovesicles for efficient delivery of chemotherapeutics to pancreatic cancer. Mol. Pharm. 11(7), 2390–2399 (2014).
  Medline CASGoogle Scholar
• 17. Sun QQ, Cheng D, Yu XS et al. A pH-sensitive polymeric nanovesicle based on biodegradable poly(ethylene glycol)-b-poly(2-(diisopropylamino)ethyl aspartate) as a MRI-visible drug delivery system. J. Mater. Chem. 21(39), 15316–15326 (2011).
  CASGoogle Scholar
• 18. Ang CY, Tan SY, Zhao YL. Recent advances in biocompatible nanocarriers for delivery of chemotherapeutic cargoes towards cancer therapy. Org. Biomol. Chem. 12(27), 4776–4806 (2014).
  Medline CASGoogle Scholar
• 19. Scaranti M, Cojocaru E, Banerjee S, Banerji U. Exploiting the folate receptor α in oncology. Nat. Rev. Clin. Oncol. 17(6), 349–359 (2020).
  MedlineGoogle Scholar
• 20. Sudimack J, Lee RJ. Targeted drug delivery via the folate receptor. Adv. Drug Deliv. Rev. 41(2), 147–162 (2000).
  Medline CASGoogle Scholar
• 21. Wang LL, Li M, Zhang N. Folate-targeted docetaxel-lipid-based-nanosuspensions for active-targeted cancer therapy. Int. J. Nanomed. 7, 3281–3294 (2012).
  Medline CASGoogle Scholar
• 22. Ghalehkhondabi V, Soleymani M, Fazlali A. Folate-targeted nanomicelles containing silibinin as an active drug delivery system for liver cancer therapy. J. Drug Deliv. Sci. Technol. 61, 102157 (2021).
  CASGoogle Scholar
• 23. Gong YC, Xiong XY, Ge XJ, Li ZL, Li YP. Effect of the folate ligand density on the targeting property of folated-conjugated polymeric nanoparticles. Macromol. Biosci. 19(2), 1800348 (2019).
  Google Scholar
• 24. Rahdar A, Hajinezhad MR, Barani M et al. Pluronic F127/doxorubicin microemulsions: preparation, characterization, and toxicity evaluations. J. Mol. Liq. 345, 117028 (2022).
  CASGoogle Scholar
• 25. Abu-Serie MM, Andrade F, Cámara-Sánchez P et al. Pluronic F127 micelles improve the stability and enhance the anticancer stem cell efficacy of citral in breast cancer. Nanomedicine 16(17), 1471–1485 (2021).
  CASGoogle Scholar
• 26. Rasal RM, Janorkar AV, Hirt DE. Poly(lactic acid) modifications. Prog. Polym. Sci. 35(3), 338–356 (2010).
  CASGoogle Scholar
• 27. Blasi P. Poly(lactic acid)/poly(lactic-co-glycolic acid)-based microparticles: an overview. J. Pharm. Invest. 49(4), 337–346 (2019).
  CASGoogle Scholar
• 28. Pan XQ, Gong YC, Li ZL, Li YP, Xiong XY. Folate-conjugated pluronic/polylactic acid polymersomes for oral delivery of paclitaxel. Int. J. Biol. Macromol. 139, 377–386 (2019).
  Medline CASGoogle Scholar
• 29. Xiong XY, Tam KC, Gan LH. Synthesis and aggregation behavior of Pluronic F127/poly(lactic acid) block copolymers in aqueous solutions. Macromolecules 36(26), 9979–9985 (2003).
  CASGoogle Scholar
• 30. Wang Y, Ma SR, Xie ZS, Zhang HS. A synergistic combination therapy with paclitaxel and doxorubicin loaded micellar nanoparticles. Colloids Surf. B Biointerfaces 116, 41–48 (2014).
  Medline CASGoogle Scholar
• 31. Xie S, Gong YC, Xiong XY et al. Targeted folate-conjugated pluronic P85/poly(lactide-co-glycolide) polymersome for the oral delivery of insulin. Nanomedicine 13(19), 2527–2544 (2018).
  CASGoogle Scholar
• 32. Chou T. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58(3), 621–681 (2006).
  Medline CASGoogle Scholar
• 33. Ejigah V, Owoseni O, Bataille-Backer P et al. Approaches to improve macromolecule and nanoparticle accumulation in the tumor microenvironment by the enhanced permeability and retention effect. Polymers 14(13), 2601 (2022).
  Medline CASGoogle Scholar
• 34. Wang H, Zhao Y, Wu Y et al. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG–PLGA copolymer nanoparticles. Biomaterials 32(32), 8281–8290 (2011).
  Medline CASGoogle Scholar
• 35. He CB, Hu YP, Yin LC, Tang C, Yin CH. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 31(13), 3657–3666 (2010).
  Medline CASGoogle Scholar
• 36. Duong HHP, Yung LYL. Synergistic co-delivery of doxorubicin and paclitaxel using multi-functional micelles for cancer treatment. Int. J. Pharm. 454(1), 486–495 (2013).
  Medline CASGoogle Scholar
• 37. Maghak L, Larsen J. Intact or in pieces? A look at how clinically approved, biodegradable block co-polymers affect blood components. ACS Biomater. Sci. Eng. 6(9), 4846–4850 (2020).
  Medline CASGoogle Scholar
• 38. Xiong XY, Tam KC, Gan LH. Hydrolytic degradation of Pluronic F127/poly (lactic acid) block copolymer nanoparticles. Macromolecules 37(9), 3425–3430 (2004).
  CASGoogle Scholar
• 39. Xiong XY, Tam KC, Gan LH. Release kinetics of hydrophobic and hydrophilic model drugs from Pluronic F127/poly (lactic acid) nanoparticles. J. Control. Rel. 103(1), 73–82 (2005).
  Medline CASGoogle Scholar
• 40. Zhu D, Wu S, Hu C et al. Folate-targeted polymersomes loaded with both paclitaxel and doxorubicin for the combination chemotherapy of hepatocellular carcinoma. Acta Biomater. 58, 399–412 (2017).
  Medline CASGoogle Scholar
• 41. Baabur-Cohen H, Vossen LI, Kruger HR et al. In vivo comparative study of distinct polymeric architectures bearing a combination of paclitaxel and doxorubicin at a synergistic ratio. J. Control. Rel. 257, 118–131 (2017).
  Medline CASGoogle Scholar
• 42. Brownlee G, Donaldson P, Pho M et al. Comparison of the cardioprotective properties of HyDOX (hyaluronan /doxorubicin) and liposomal doxorubicin. Cancer Res. 67(Suppl. 9), 4060 (2007).
  Google Scholar
• 43. Wang YW, Zhang HY, Hao J et al. Lung cancer combination therapy: co-delivery of paclitaxel and doxorubicin by nanostructured lipid carriers for synergistic effect. Drug Deliv. 23(4), 1398–1403 (2016).
  Medline CASGoogle Scholar
• 44. Zhang Y, Zhang H, Wu WB et al. Folate-targeted paclitaxel-conjugated polymeric micelles inhibits pulmonary metastatic hepatoma in experimental murine H22 metastasis models. Int. J. Nanomed. 9, 2019–2030 (2014).
  MedlineGoogle Scholar
• 45. Lv SX, Tang ZH, Li MQ et al. Co-delivery of doxorubicin and paclitaxel by PEG–polypeptide nanovehicle for the treatment of non-small-cell lung cancer. Biomaterials 35(23), 6118–6129 (2014).
  Medline CASGoogle Scholar
• 46. Lehár J, Krueger AS, Avery W et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat. Biotechnol. 27(7), 659–666 (2009).
  Medline CASGoogle Scholar
• 47. Pang ZQ, Feng L, Hua RR et al. Lactoferrin-conjugated biodegradable polymersome holding doxorubicin and tetrandrine for chemotherapy of glioma rats. Mol. Pharm. 7(6), 1995–2005 (2010).
  Medline CASGoogle Scholar